Related Experiment Video
Updated: Apr 26, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
Published on: August 10, 2017
Evaluation of class I HDAC isoform selectivity of largazole analogues
Bumki Kim1, Heekwang Park1, Lilibeth A Salvador2
1Department of Chemistry, Duke University, Durham, NC 27708, United States.
Abstract:
Largazole is a potent class I selective histone deacetylase (HDAC) inhibitor. The majority of largazole analogues to date have modified the thiazole-thiazoline and the warhead moiety. In order to elucidate class I-specific structure-activity relationships, a series of analogues with modifications in the valine or the linker region were prepared and evaluated for their class I isoform selectivity. The inhibition profile showed that the C2 position of largazole has an optimal steric requirement for efficient HDAC inhibition and that substitution of the trans-alkene in the linker with an aromatic group results in complete loss of activity. This data will aid the design of class I isoform selective HDAC inhibitors.
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Anthelminthic Agents
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Dose-Response Relationship: Selectivity and Specificity
Bioequivalence of Drugs: Drugs with Multiple Indications

